SG7001 Strategy Operations and Partnerships
4a
| Stage in the industry life cycle (just its title) | Shake-out stage |
| Implications | Sothema Pharmaceuticals is currently in its shake-out stage in the industry life cycle. The organisation has been operating in the markets since 1976 and with time the growth of the company has subsided (Sothema, 2022). This implies that the company is close to its maturity stage and might face difficulties in further growth. |
4b
| Issue | Survival factor | Success factor |
| Excessive demand for vaccines | With the onset of covid-19 vaccination the pharma companies have seen major growth and thus partnering up with major pharma companies can help Sothema to gain the licence to manufacture covid-19 vaccines (Rosa et al. 2021) | The company has already received support from the Moroccan government for supporting the vaccination drive in the country The company also manufactures vaccines for China (Reuters, 2021). These are the major success factors in the recent time period. |
| Research and development towards viral resistant drugs | Pharma companies are working towards the development of viral resist drugs that can help to prevent or minimise the impact of viral diseases (Takashita et al. 2022) | Sothema needs to adopt similar approaches in order to cater to the increased demands of viral resistant drugs (Martinez, 2022) |
| Global distribution capability | The demand for medicines in the global market has increased substantially and companies with a global presence have a better chance of surviving in the market (Soulsby and Kennedy, 2022). | Sothema can expand its operation in different European countries and build a robust distribution network that would help the company to compete against global pharma companies and this would be a major success factor (Andriani and Cattani, 2022) |
| Use of AI and technology | The use of technology has become far and wide in however gaining access to the same has become difficult (Shenoy et al. 2022) | Sothema needs to incorporate innovation in and make use of existing technology or achieve a technology transfer from other pharma companies in the industry which would help them to succeed in the long run (Saha et al. 2022). |
References
Andriani, P. and Cattani, G., (2022). Functional diversification and exaptation: the emergence of new drug uses in the pharma industry. Industrial and Corporate Change.
Martinez, M.A., (2022). Efficacy of repurposed antiviral drugs: lessons from COVID-19. Drug Discovery Today.
Reuters, (2021). Morocco’s Sothema to produce China’s Sinopharm vaccine. [Online]. Available at: https://www.reuters.com/business/healthcare-pharmaceuticals/moroccos-sothema-produce-chinas-sinopharm-vaccine-2021-07-05/ [Accessed 23 July 2022]
Rosa, S.S., Prazeres, D.M., Azevedo, A.M. and Marques, M.P., (2021). mRNA vaccines manufacturing: Challenges and bottlenecks. Vaccine, 39(16), pp.2190-2200.
Saha, E., Rathore, P., Parida, R. and Rana, N.P., (2022). The interplay of emerging technologies in pharmaceutical supply chain performance: An empirical investigation for the rise of Pharma 4.0. Technological Forecasting and Social Change, 181, p.121768.
Schuhmacher, A., Gatto, A., Hinder, M., Kuss, M. and Gassmann, O., 2020. The upside of being a digital pharma player. Drug discovery today, 25(9), pp.1569-1574.
Shenoy, S.S., Shenoy, S., Sreedhar D, S.D., Ankitha Shetty, A.S., Rao, R.R., Rao, R., D’SOUZA, K.J. and D’SOUZA, J.E.N.I.F.E.R., (2022). Traceability of counterfeit drugs in pharma supply chain through Blockchain Technology A Systematic Review of the Evidence. Research Journal of Pharmacy and Technology, pp.1-5.
Sothema, (2022). United energies for life. [Online]. Available at: https://sothema.com/web/ [Accessed 23 July 2022]
Soulsby, C. and Kennedy, A., (2022). A New Route to Pharma GDP Compliance and Standardisation.
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H. and Saito, M., (2022). Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. New England Journal of Medicine, 386(10), pp.995-998.
Know more about UniqueSubmission’s other writing services:
